![Hendrik Zonnenberg](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Hendrik Zonnenberg
Chief Investment Officer bij Multifund BV
Profiel
Hendrik Zonnenberg is currently the Director of Investments at Multifund BV and a Member-Supervisory Board at ISA Pharmaceuticals BV.
He previously worked as an Analyst at ING Bank NV (Broker) in 2005.
He graduated from the University of Groningen with a degree.
Actieve functies van Hendrik Zonnenberg
Bedrijven | Functie | Begin |
---|---|---|
Multifund BV
![]() Multifund BV Investment ManagersFinance Multifund BV is an independent investment adviser headquartered in Reeuwijk, Netherlands and was founded in 2002. Multifund manages diversified assets. | Chief Investment Officer | - |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Directeur/Bestuurslid | - |
Eerdere bekende functies van Hendrik Zonnenberg
Bedrijven | Functie | Einde |
---|---|---|
ING Bank NV (Broker)
![]() ING Bank NV (Broker) Investment Banks/BrokersFinance ING Bank NV (Broker) (ING Bank-Broker) is the broker-dealer division of ING Bank NV, an investment bank headquartered in Amsterdam, Netherlands. It is a wholly-owned subsidiary of ING Groep N.V. (AMS: INGA; NYSE: ING), a Dutch multinational banking and financial services corporation. The firm was founded in 1991 through the merger of Nationale-Nederlanden and NMB Postbank Groep. ING Bank-Broker provides brokerage services to institutions, large corporations, and medium-sized companies. | Analyst-Equity | 18-10-2005 |
Opleiding van Hendrik Zonnenberg
University of Groningen | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 3 |
---|---|
ING Bank NV (Broker)
![]() ING Bank NV (Broker) Investment Banks/BrokersFinance ING Bank NV (Broker) (ING Bank-Broker) is the broker-dealer division of ING Bank NV, an investment bank headquartered in Amsterdam, Netherlands. It is a wholly-owned subsidiary of ING Groep N.V. (AMS: INGA; NYSE: ING), a Dutch multinational banking and financial services corporation. The firm was founded in 1991 through the merger of Nationale-Nederlanden and NMB Postbank Groep. ING Bank-Broker provides brokerage services to institutions, large corporations, and medium-sized companies. | Finance |
Multifund BV
![]() Multifund BV Investment ManagersFinance Multifund BV is an independent investment adviser headquartered in Reeuwijk, Netherlands and was founded in 2002. Multifund manages diversified assets. | Finance |
ISA Pharmaceuticals BV
![]() ISA Pharmaceuticals BV Pharmaceuticals: MajorHealth Technology ISA Pharmaceuticals BV operates as a clinical-stage immunotherapy company. The firm develops novel therapeutic vaccines for cancer and infectious diseases. Its product portfolio builds on its proprietary SLP-technology (Synthetic Long Peptide) for the development of therapeutic vaccines. The firm holds the exclusive rights to LUMC's patent families for amongst others, the development of therapeutic vaccines. The company was founded by Cornelis J. M. Melief in 2004 and is headquartered in Leiden, the Netherlands. | Health Technology |